Julie Paik, MD
Internal Medicine · Baltimore, MDNPI 1407032378
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $71,825 of the $76,363 with a category attached, or 94.1%. 9 manufacturers reported payments, led by Pfizer at 55.4% of the total. Among internal medicine clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 30 payments — averaging $2545.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$42K
- Argenx US, Inc.$11K
- Boehringer Ingelheim$9K
- Boehringer Ingelheim International GmbH$6K
- AstraZeneca$6K
- EMD Serono, Inc.$1K
- plus $219 from 3 others
Across 54 payments — averaging $17,725 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$449K
- TG Therapeutics, Inc.$280K
- AstraZeneca$154K
- Argenx US, Inc.$74K
What the payments were for
- Consulting fees$71,82594%
- Travel & lodging$3,8235%
- Food & beverage$7151%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 4 | $42,288 |
| Argenx US, Inc. | 5 | $10,635 |
| Boehringer Ingelheim | 8 | $9,340 |
| Boehringer Ingelheim International GmbH | 3 | $6,438 |
| AstraZeneca(2 entities) | 4 | $6,094 |
| EMD Serono, Inc. | 2 | $1,350 |
| TG Therapeutics, Inc. | 2 | $128 |
| Octapharma USA, Inc. | 1 | $69 |
| Amgen | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$76,363 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 52 | $1,229,952 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 58 | $568,398 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 22 | $436,985 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 49 | $432,437 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 24 | $99,873 |
| Mycophenolate Mofetil | 65 | $14,471 |
| Mycophenolic AcidMycophenolate Sodium | 32 | $11,361 |
| Sildenafil Citrate | 11 | $6,297 |
| MethotrexateMethotrexate Sodium | 59 | $3,280 |
| Hydroxychloroquine Sulfate | 27 | $1,501 |
| Prednisone | 50 | $633 |
| Pantoprazole Sodium | 12 | $354 |
| Gabapentin | 12 | $193 |
| Sodium Chloride0.9 % Sodium Chloride | 11 | $155 |
| Triamcinolone Acetonide | 12 | $91 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam | $42,288 | $436,98522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Baltimore
- Param DedhiaBaltimore$636K
- Shawn DhillonBaltimore$227K
- Jeremy SugarmanBaltimore$210K
- Charles FlexnerBaltimore$133K
- Kristen MarroneBaltimore$97K
- Ana-Maria OrbaiBaltimore$89K
- Mark YarchoanBaltimore$89K
- David Muniz PedrogoBaltimore$82K
- Allison AgwuBaltimore$58K
- Jeffrey ThiboutotBaltimore$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.